- Home
- CNTB vs TIL Comparison
CNTB vs TIL Comparison
Compare CNTB & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTB | TIL |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.6M | 74.7M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CNTB | TIL |
|---|---|---|
| Price | $2.68 | $8.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | $8.50 | ★ $125.00 |
| AVG Volume (30 Days) | ★ 110.5K | 39.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.22 | 52.54 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $26,033,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $24,617.69 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.51 | $5.67 |
| 52 Week High | $3.28 | $42.75 |
Technical Indicators
Market Signals| Indicator | CNTB | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 51.52 | 45.02 |
| Support Level | $2.09 | $8.14 |
| Resistance Level | $2.86 | $9.81 |
| Average True Range (ATR) | 0.20 | 0.56 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 44.78 | 17.05 |
Price Performance
Historical ComparisonAbout CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.